entertainment -WSS

entertainment

author：explore 2025-10-02 06:02:21 - browse：91561

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

LONDON — A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, its developers said Monday, as the competition in the broader obesity medicine field pushes ahead.

The drug, survodutide, is being developed by the privately held German firm Boehringer Ingelheim and the Danish biotech Zealand Pharma. Zealand’s share price has doubled over the past year over the potential of the drug, and on Monday morning, shares jumped another 25%.

In the study, 83% of patients with a condition called MASH and who were treated with survodutide saw significant improvements in their disease compared to 18% of those who received placebo. The study met its primary endpoint of improvements in MASH after 48 weeks without the worsening of fibrosis, a scarring of the liver, the companies said. Secondary endpoints were also met, including an improvement in fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Food makers to regulators: Ultra

focus

WSS

Can food be medicine? And other questions about a new push

Grail is spending more than ever lobbying Congress

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Bacterial infection may be ‘key event’ in endometriosis, study says

How medical schools plan to diversify without affirmative action

hotspot

entertainment

entertainment

Apple is now the first public company to be valued at $3 trillion

Listen: Biogen's messy board & Laronde's data problem

State Dept. review finds Biden bears some blame for Afghanistan failures

A new study asks: Are we harming blood donors by taking blood?

Cancer drug shortages should be causing more outrage

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Medicare proposal to cover medical devices draws a mixed reaction

What to make of Biden’s latest efforts on cancer research

Medical leaders decry Supreme Court decision on affirmative action

Van's Gluten Free Original Waffles recalled for possible wheat allergen

focus

Food makers tried to stack nutrition panel with preferred experts

Telehealth for opioid use disorder is lifesaving

Private equity could exacerbate cardiology's overuse problem, experts fear

Inside the fall of star MIT scientist David Sabatini

What to make of Biden’s latest efforts on cancer research

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

focus

knowledge

focus

hotspot